{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:01:48Z","timestamp":1780354908336,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s13730-020-00558-7","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T07:03:13Z","timestamp":1609657393000},"page":"287-293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Minimal change disease concurrent with acute interstitial nephritis after long-term use of sorafenib in a patient with renal cell carcinoma"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9554-3646","authenticated-orcid":false,"given":"Katsuhito","family":"Ihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatemitsu","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"issue":"2","key":"558_CR1","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","volume":"30","author":"CC Estrada","year":"2019","unstructured":"Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol. 2019;30(2):187\u2013200.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"558_CR2","doi-asserted-by":"publisher","first-page":"E2073","DOI":"10.3390\/ijms17122073","volume":"17","author":"A Semeniuk-Wojta\u015b","year":"2016","unstructured":"Semeniuk-Wojta\u015b A, Lubas A, Stec R, et al. Influence of tyrosine kinase inhibitors on hypertension and nephrotoxicity in metastatic renal cell cancer patients. Int J Mol Sci. 2016;17(12):E2073.","journal-title":"Int J Mol Sci"},{"key":"558_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10157-009-0167-5","volume":"13","author":"IJ Jonkers","year":"2009","unstructured":"Jonkers IJ, van Buren M. Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma. Clin Exp Nephrol. 2009;13:397\u2013401.","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"558_CR4","doi-asserted-by":"publisher","first-page":"e90135","DOI":"10.1371\/journal.pone.0090135","volume":"9","author":"ZF Zhang","year":"2014","unstructured":"Zhang ZF, Wang T, Liu LH, et al. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS ONE. 2014;9(3):e90135.","journal-title":"PLoS ONE"},{"issue":"4","key":"558_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11523-015-0368-7","volume":"10","author":"A Abbas","year":"2015","unstructured":"Abbas A, Mirza MM, Ganti AK, et al. Renal toxicities of targeted therapies. Target Oncol. 2015;10(4):487\u201399.","journal-title":"Target Oncol"},{"key":"558_CR6","first-page":"173","volume-title":"Heptinstall's pathology of the kidney","author":"JL Olson","year":"2014","unstructured":"Olson JL. The nephrotic syndrome and minimal change disease. In: Jennette JC, D\u2019Agati VD, Olson JL, Silva FG, editors. Heptinstall\u2019s pathology of the kidney. Philadelphia: Lippincott Williams & Wilkins; 2014. p. 173\u2013205."},{"issue":"Suppl 6","key":"558_CR7","first-page":"52","volume":"18","author":"RJ Glassock","year":"2003","unstructured":"Glassock RJ. Secondary minimal change disease. Nephrol Dial Transpl. 2003;18(Suppl 6):52\u20138.","journal-title":"Nephrol Dial Transpl."},{"issue":"1","key":"558_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13730-014-0135-0","volume":"4","author":"T Kaneko","year":"2015","unstructured":"Kaneko T, Shimizu A, Aoki M, et al. A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma. CEN Case Rep. 2015;4(1):31\u20137.","journal-title":"CEN Case Rep"},{"issue":"3","key":"558_CR9","first-page":"179","volume":"54","author":"A Schwarz","year":"2000","unstructured":"Schwarz A, Krause PH, Kunzendorf U, et al. The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis. Clin Nephrol. 2000;54(3):179\u201390.","journal-title":"Clin Nephrol"},{"issue":"1","key":"558_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12882-018-1074-3","volume":"19","author":"Y Furuto","year":"2018","unstructured":"Furuto Y, Hashimoto H, Namikawa A, et al. Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report. BMC Nephrol. 2018;19(1):273.","journal-title":"BMC Nephrol"},{"issue":"7","key":"558_CR11","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2169\/internalmedicine.54.3661","volume":"54","author":"K Maruyama","year":"2015","unstructured":"Maruyama K, Chinda J, Kuroshima T, et al. Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib. Intern Med. 2015;54(7):823\u20136.","journal-title":"Intern Med"},{"key":"558_CR12","doi-asserted-by":"publisher","first-page":"bcr2013201183","DOI":"10.1136\/bcr-2013-201183","volume":"2014","author":"KI Quintyne","year":"2014","unstructured":"Quintyne KI, Neenan T, Casserly L, et al. Uncommon side effect with a commonly used targeted agent: sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma. BMJ Case Rep. 2014;2014:bcr2013201183.","journal-title":"BMJ Case Rep."},{"issue":"2","key":"558_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ki.2013.344","volume":"85","author":"H Izzedine","year":"2014","unstructured":"Izzedine H, Mangier M, Ory V, et al. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int. 2014;85(2):457\u201370.","journal-title":"Kidney Int"},{"key":"558_CR14","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S1097-2765(00)80057-X","volume":"1","author":"M Kestil\u00e4","year":"1998","unstructured":"Kestil\u00e4 M, Lenkkeri U, M\u00e4nnikk\u00f6 M, et al. Positionally cloned gene for a novel glomerular protein\u2014nephrin\u2014Is mutated in congenital nephrotic syndrome. Mol Cell. 1998;1:575\u201382.","journal-title":"Mol Cell"},{"key":"558_CR15","first-page":"267","volume":"70","author":"ES den Deurwaarder","year":"2012","unstructured":"den Deurwaarder ES, Desar IM, Steenbergen EJ, et al. Kidney injury during VEGF inhibitor therapy. Neth J Med. 2012;70:267\u201371.","journal-title":"Neth J Med"},{"key":"558_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","volume":"46","author":"H Izzedine","year":"2010","unstructured":"Izzedine H, Massard C, Spano JP, et al. VEGF signaling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer. 2010;46:439\u201348.","journal-title":"Eur J Cancer"},{"key":"558_CR17","first-page":"1738","volume":"11","author":"W Kriz","year":"1996","unstructured":"Kriz W. Progressive renal failure\u2013inability of podocytes to replicate and the consequences for development of glomerulosclerosis. Nephrol Dial Transpl. 1996;11:1738\u201342.","journal-title":"Nephrol Dial Transpl"},{"key":"558_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1046\/j.1523-1755.1998.00044.x","volume":"54","author":"W Kriz","year":"1998","unstructured":"Kriz W, Gretz N, Lemley KV. Progression of glomerular disease: is the podocyte the culprit? Kidney Int. 1998;54:687\u201397.","journal-title":"Kidney Int"},{"key":"558_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/annonc\/mdp472","volume":"21","author":"EN Overkleeft","year":"2010","unstructured":"Overkleeft EN, Goldschmeding R, van Reekum F, et al. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol. 2010;21:184\u20135.","journal-title":"Ann Oncol"},{"key":"558_CR20","first-page":"1111","volume-title":"Heptinstall\u2019s Pathology of the kidney","author":"SV Brodsky","year":"2014","unstructured":"Brodsky SV, Nadasdy T. Acute and chronic tubulointerstitial Nephritis. In: Jennette JC, D\u2019Agati VD, Olson JL, Silva FG, editors. Heptinstall\u2019s Pathology of the kidney. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2014. p. 1111\u201365.","edition":"7"},{"key":"558_CR21","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nm.1857","volume":"14","author":"C Faul","year":"2008","unstructured":"Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the anti-proteinuric effect of cyclosporine A. Nat Med. 2008;14:931\u20138.","journal-title":"Nat Med"},{"key":"558_CR22","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1345\/aph.1H244","volume":"40","author":"M Dincer","year":"2006","unstructured":"Dincer M, Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother. 2006;40:2278\u20139.","journal-title":"Ann Pharmacother"},{"key":"558_CR23","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/sj.ki.5001655","volume":"70","author":"CY Xing","year":"2006","unstructured":"Xing CY, Saleem MA, Coward RJ, et al. Direct effects of dexamethasone on human podocytes. Kidney Int. 2006;70:1038\u201345.","journal-title":"Kidney Int"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00558-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-020-00558-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00558-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T14:07:21Z","timestamp":1617458841000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-020-00558-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["558"],"URL":"https:\/\/doi.org\/10.1007\/s13730-020-00558-7","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"7 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient in this case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}